In-Kyu Lee
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
In-Kyu Lee has a total of 33 co-authors. Here are the top co-authors by number of shared publications:
J. D. Ahn
Keimyung University
2 shared publicationsC. D. Kim
Pusan National University
1 shared publicationChun-Soo Kim
From the Departments of Internal Medicine (M.-J.K., K.-G.P., K.-M.L., H.-S.K., I.-K.L.) and Institute for Medical Science, Physiology (S.-Y.K.), and Pediatrics (C.-S.K., S.-L.L.), Keimyung University School of Medicine, Daegu; Department of Pathology (Y.-C.C.), Catholic University of Daegu, School of Medicine, Daegu; and the Department of Internal Medicine (J.-Y.P., K.-I.U.), University of Ulsan College of Medicine, Seoul, Korea
1 shared publicationH-G. Kang
Keimyung University
1 shared publicationH-J. Kim
Keimyung University
1 shared publicationH-S. Kim
Keimyung University
1 shared publication
Latest Publications
- Open Access
- 13 April 2005
- Published by Springer Nature in Diabetologia
- Vol. 48 (5) , 1022-1028
The effects of the overexpression of recombinant uncoupling protein 2 on proliferation, migration and plasminogen activator inhibitor 1 expression in human vascular smooth muscle cells
Increased oxidative stress in vascular smooth muscle cells (VSMCs) has been implicated in the pathogenesis of accelerated atherosclerosis in patients with diabetes mellitus. Uncoupling protein 2 (UCP-2) is an important regulator of intracellular reactive oxygen species (ROS) production. We hypothesised that UCP-2 functions as an inhibitor of the atherosclerotic process in VSMCs.
- 13 April 2005
- Published by Springer Nature in Diabetologia
- Vol. 48 (5) , 1022-1028
Open AccessThe effects of the overexpression of recombinant uncoupling protein 2 on proliferation, migration and plasminogen activator inhibitor 1 expression in human vascular smooth muscle cells
Increased oxidative stress in vascular smooth muscle cells (VSMCs) has been implicated in the pathogenesis of accelerated atherosclerosis in patients with diabetes mellitus. Uncoupling protein 2 (UCP-2) is an important regulator of intracellular reactive oxygen species (ROS) production. We hypothesised that UCP-2 functions as an inhibitor of the atherosclerotic process in VSMCs.
- Open Access
- 1 April 2005
- Published by Wolters Kluwer Health in Hypertension
- Vol. 45 (4) , 552-556
Cilostazol Inhibits Vascular Smooth Muscle Cell Growth by Downregulation of the Transcription Factor E2F
Neointimal formation, the leading cause of restenosis, is caused by proliferation of vascular smooth muscle cells (VSMCs). Patients with diabetes mellitus have higher restenosis rates after coronary angioplasty than nondiabetic patients. Cilostazol, a selective type 3 phosphodiesterase inhibitor, is currently used to treat patients with diabetic vascular complications. Cilostazol is a potent antiplatelet agent that inhibits VSMC proliferation. In the present study, we examine whether the antiproliferative effect of cilostazol on VSMCs is mediated by inhibition of an important cell cycle transcription factor, E2F. Cilostazol inhibited the proliferation of human VSMCs in response to high glucose in vitro and virtually abolished neointimal formation in rats subjected to carotid artery injury in vivo. Moreover, the compound suppressed high-glucose–induced E2F–DNA binding activity, and the expression of E2F1, E2F2, cyclin A, and PCNA proteins. These data suggest that the beneficial effects of cilostazol on high-glucose–stimulated proliferation of VSMCs are mediated by the downregulation of E2F activity and expression of its downstream target genes, including E2F1, E2F2, cyclin A, and PCNA.
- 1 April 2005
- Published by Wolters Kluwer Health in Hypertension
- Vol. 45 (4) , 552-556
Open AccessCilostazol Inhibits Vascular Smooth Muscle Cell Growth by Downregulation of the Transcription Factor E2F
Neointimal formation, the leading cause of restenosis, is caused by proliferation of vascular smooth muscle cells (VSMCs). Patients with diabetes mellitus have higher restenosis rates after coronary angioplasty than nondiabetic patients. Cilostazol, a selective type 3 phosphodiesterase inhibitor, is currently used to treat patients with diabetic vascular complications. Cilostazol is a potent antiplatelet agent that inhibits VSMC proliferation. In the present study, we examine whether the antiproliferative effect of cilostazol on VSMCs is mediated by inhibition of an important cell cycle transcription factor, E2F. Cilostazol inhibited the proliferation of human VSMCs in response to high glucose in vitro and virtually abolished neointimal formation in rats subjected to carotid artery injury in vivo. Moreover, the compound suppressed high-glucose–induced E2F–DNA binding activity, and the expression of E2F1, E2F2, cyclin A, and PCNA proteins. These data suggest that the beneficial effects of cilostazol on high-glucose–stimulated proliferation of VSMCs are mediated by the downregulation of E2F activity and expression of its downstream target genes, including E2F1, E2F2, cyclin A, and PCNA.
- 4 November 2004
- Published by Wiley in Proteomics
- Vol. 4 (11) , 3383-3393
Analysis of proteome and transcriptome of tumor necrosis factor α stimulated vascular smooth muscle cells with or without alpha lipoic acid
Vascular smooth muscle cells (VSMCs) play an important role in the development and progression of atherosclerosis. Tumor necrosis factor α (TNFα), a cytokine secreted by VSMCs and macrophages in atherosclerotic lesions, regulates a variety of cellular functions of inflammatory cells and VSMCs by promoting cell growth and motility, which are critical for the initiation and progression of vascularlesions. Alpha lipoic acid (ALA), a well known antioxidant, acts as a pyruvate dehydrogenase cofactor in mitochondrial metabolism. Recently, we reported that ALA has many beneficial effects on vascular cells in atherosclerosis. The aim of the current study was to examine VSMCs, treated for 24 hours with TNFα (10 ng/mL) in the presence or absence of ALA (2 mM), for differential protein and genes expression using two‐dimensional gel electrophoresis (2‐DE) and DNA microarray analysis, respectively. Using 2‐DE, we identified proteins whose expression changed by at least 2.5‐fold after TNFα stimulation. Proteins up‐regulated by TNFα that were subsequently down‐regulated in the presence of ALA were identified by matrix‐assisted laser desorption/ionization‐time of flight mass spectrometry as plasminogen activator inhibitor‐2, fetal liver LKB‐interacting protein, osteoblast‐specific factor 2, glucosidase II, cyclin‐dependent kinase 3, endoplasmin precursor and glutathione synthetase. TNFα down‐regulated proteins that were up‐regulated in the presence of ALA were keratin 19, eukaryotic translation elongation factor and Rho GDP dissociation inhibitor α. Gene expression analysis using DNA microarray tools confirmed the up‐regulation or down‐regulation of some, but not all, of the proteins observed in ALA challenged, TNFα‐treated cells. This data should provide valuable information about the underlying mechanisms of atherosclerosis.
- 4 November 2004
- Published by Wiley in Proteomics
- Vol. 4 (11) , 3383-3393
Analysis of proteome and transcriptome of tumor necrosis factor α stimulated vascular smooth muscle cells with or without alpha lipoic acid
Vascular smooth muscle cells (VSMCs) play an important role in the development and progression of atherosclerosis. Tumor necrosis factor α (TNFα), a cytokine secreted by VSMCs and macrophages in atherosclerotic lesions, regulates a variety of cellular functions of inflammatory cells and VSMCs by promoting cell growth and motility, which are critical for the initiation and progression of vascularlesions. Alpha lipoic acid (ALA), a well known antioxidant, acts as a pyruvate dehydrogenase cofactor in mitochondrial metabolism. Recently, we reported that ALA has many beneficial effects on vascular cells in atherosclerosis. The aim of the current study was to examine VSMCs, treated for 24 hours with TNFα (10 ng/mL) in the presence or absence of ALA (2 mM), for differential protein and genes expression using two‐dimensional gel electrophoresis (2‐DE) and DNA microarray analysis, respectively. Using 2‐DE, we identified proteins whose expression changed by at least 2.5‐fold after TNFα stimulation. Proteins up‐regulated by TNFα that were subsequently down‐regulated in the presence of ALA were identified by matrix‐assisted laser desorption/ionization‐time of flight mass spectrometry as plasminogen activator inhibitor‐2, fetal liver LKB‐interacting protein, osteoblast‐specific factor 2, glucosidase II, cyclin‐dependent kinase 3, endoplasmin precursor and glutathione synthetase. TNFα down‐regulated proteins that were up‐regulated in the presence of ALA were keratin 19, eukaryotic translation elongation factor and Rho GDP dissociation inhibitor α. Gene expression analysis using DNA microarray tools confirmed the up‐regulation or down‐regulation of some, but not all, of the proteins observed in ALA challenged, TNFα‐treated cells. This data should provide valuable information about the underlying mechanisms of atherosclerosis.
- 1 November 2003
- Published by Bentham Science Publishers Ltd. in Current Drug Targets
- Vol. 4 (8) , 619-623
Advantages of the circular dumbbell decoy in gene therapy and studies of gene regulation.
Abstract: Decoy oligodeoxynucleotides (ODN) that can reduce the trans-activity of transcription factors may be highly useful in gene therapy and the study of transcriptional regulation. Several different types of these double-stranded DNA decoys have been developed, including unmodified oligonucleotide duplexes, αβ-anomeric oligonucleotides, and oligonucleotide duplexes with methylphosphonate- and phosphorothioate-modified linkages. The latter ODNs have been particularly extensively studied but suffer from a number of limitations, including their insensitivity to polymerases, their lack of sequence specificity, and their tendency to activate immune responses. To resolve these problems, circular dumbbell (CD) double-stranded ODNs were developed. These CD ODNs are constructed by the circularization of the 3 and 5 ends of the oligonucleotides and enzymatic ligation. They exhibit high resistance to nucleases, are easily taken up by cells, and have a nontoxic unmodified backbone that resembles natural DNA. In this article, we review the method of constructing CD ODNs and their advantages compared to other modified ODNs for use as transcription decoys.
- 1 November 2003
- Published by Bentham Science Publishers Ltd. in Current Drug Targets
- Vol. 4 (8) , 619-623
Advantages of the circular dumbbell decoy in gene therapy and studies of gene regulation.
Abstract: Decoy oligodeoxynucleotides (ODN) that can reduce the trans-activity of transcription factors may be highly useful in gene therapy and the study of transcriptional regulation. Several different types of these double-stranded DNA decoys have been developed, including unmodified oligonucleotide duplexes, αβ-anomeric oligonucleotides, and oligonucleotide duplexes with methylphosphonate- and phosphorothioate-modified linkages. The latter ODNs have been particularly extensively studied but suffer from a number of limitations, including their insensitivity to polymerases, their lack of sequence specificity, and their tendency to activate immune responses. To resolve these problems, circular dumbbell (CD) double-stranded ODNs were developed. These CD ODNs are constructed by the circularization of the 3 and 5 ends of the oligonucleotides and enzymatic ligation. They exhibit high resistance to nucleases, are easily taken up by cells, and have a nontoxic unmodified backbone that resembles natural DNA. In this article, we review the method of constructing CD ODNs and their advantages compared to other modified ODNs for use as transcription decoys.